Skip to main content

Table 2 Description of suspected or proven invasive candidiasis episodes and outcomes in patients receiving antifungals as either empirical or definite therapy according to local guidelines

From: Empirical antifungal therapy with an echinocandin in critically-ill patients: prospective evaluation of a pragmatic Candida score-based strategy in one medical ICU

  Empirical therapy (n = 39) Definite therapy (n = 12) p
Time elapsed between ICU admission and AFT (days) 8.8 (9.9) 9.0 (6.8) 0.96
Time between BC and AFT (days)* 0.4 (0.5) 2.8 (0.8) <0.01
AFT duration (days) 9.2 (6.0) 9.1 (6.4) 0.95
Echinocandin therapy duration (days) 6.7 (4.7) 5.7 (4.2) 0.54
Fluconazole therapy duration (days) 2.6 (5.1) 3.4 (5.2) 0.62
Septic shock (N. [%]) 31 (79.5) 6 (50.0) 0.04
RRT (N. [%]) 22 (56.4) 4 (33.3) 0.16
SOFA D1 8.8 (3.0) 8.4 (3.0) 0.14
PCT D1 (pg/L) 3.6 (6.6) 4.2 (10.6) 0.56
Proven bacterial infection prior to AFT (N. [%]) 14 (46.7) 9 (42.8) 0.79
Outcomes Length of ICU stay (days) 21.4 (15.7) 25.6 (22.4) 0.47
MV duration (days) 15.7 (13.3) 22.4 (24.7) 0.22
Vasoactive support duration while receiving AFT (days) 3.8 (2.9) 2.3 (2.6) 0.11
ICU mortality (N. [%]) 20 (51.2) 6 (50.0) 0.93
In-hospital mortality (N. [%]) 25 (64.1) 9 (75.0) 0.14
  1. *including the only patients with candidemia.
  2. ICU: intensive care unit; AFT: antifungal therapy; BC: blood culture; MV: mechanical ventilation; SOFA: sequential organ failure assessment; PCT: procalcitonin; RRT: renal replacement therapy.